Beam Therapeutics (BEAM) Income from Continuing Operations (2019 - 2026)
Beam Therapeutics (BEAM) posted quarterly Income from Continuing Operations of 98308000.0 for Q1 2026, up 10.25% year-over-year from 89167177.81 in Q1 2025, and down 137.65% quarter-over-quarter from 261096000.0 in Q4 2025.
Powered by 
Analysis
Beam Therapeutics (BEAM) Income from Continuing Operations (2019 - 2026) Analysis & Trends
Beam Therapeutics (BEAM) has reported Income from Continuing Operations for 8 consecutive years, with 98308000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 10.25% year-over-year to 98308000.0; the TTM figure through Mar 2026 stood at 52231000.0 (up 86.52% YoY), while the FY2025 annual figure was 63193000.0, up 83.23% from the prior year.
- Income from Continuing Operations retreated to 98308000.0 in Q1 2026 per BEAM's latest filing, from 261096000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 261096000.0 in Q4 2025 and bottomed at 176199000.0 in Q2 2022.
- Historically, Income from Continuing Operations has averaged 61886529.41 across 5 years, with a median of 92710000.0 in 2024.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations slumped 199.01% — and 2023, when it soared 472.27%.
- Beam Therapeutics' Income from Continuing Operations stood at 38349000.0 in 2022, then jumped by 472.27% to 142763000.0 in 2023, then sank by 163.29% to 90354000.0 in 2024, then soared by 388.97% to 261096000.0 in 2025, then plunged by 137.65% to 98308000.0 in 2026.
- Business Quant data shows BEAM's Income from Continuing Operations at 98308000.0 in Q1 2026, 261096000.0 in Q4 2025, and 112728000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Beam Therapeutics | 3.10 Bn | 3.10 Bn | - | -119.07 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -119.07 Mn |
| Mar 31, 2026 | -97.35 Mn |
| Dec 31, 2025 | 261.10 Mn |
| Sep 30, 2025 | -112.73 Mn |
| Jun 30, 2025 | -102.29 Mn |
| Mar 31, 2025 | -109.42 Mn |
| Dec 31, 2024 | -90.35 Mn |
| Sep 30, 2024 | -96.67 Mn |
| Jun 30, 2024 | -91.05 Mn |
| Mar 31, 2024 | -92.28 Mn |
| Dec 31, 2023 | 142.76 Mn |
| Sep 30, 2023 | -96.09 Mn |
| Jun 30, 2023 | -82.78 Mn |
| Mar 31, 2023 | -88.97 Mn |
| Dec 31, 2022 | -38.35 Mn |
| Sep 30, 2022 | -84.08 Mn |
| Jun 30, 2022 | -79.91 Mn |
| Mar 31, 2022 | -75.58 Mn |
| Dec 31, 2021 | -64.71 Mn |
| Sep 30, 2021 | -28.12 Mn |